BASEL- Alcon, a division of Novartis AG, said Wednesday that it has acquired Tear Film Innovations, Inc., a privately-held company and manufacturer of the iLux Device, a therapeutic device used to treat Meibomian Gland Dysfunction, a leading cause of dry eye. The iLux Device received 510 clearance from the U.S. Food and Drug Administration in Decem
Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company signed a license agreement with Daewoong Pharmaceutical Co., Ltd. for development of BBT-401, the first anti-Pellino-1 compound currently under development for ulcerative colitis treatment. In return, Daewoong...
Lewes, DE 12/18/2018 Diabetic Foot Ulcer Pipeline Analysis report gives comprehensive insights on the various drugs being developed for the treatment of DFU. The report covers all the drugs that are in various phases of development. The pipeline focuses on novel pharmacologic drugs and regenerative medicines covering, antibodies, stem cell th
The bill from Mrs. Warren, a Massachusetts Democrat and potential White House contender, would set up a manufacturing office within the Health and Human Services Department to make select drugs and offer them at an affordable price. "In market after market, competition is dying as a handful of giant companies spend millions to rig the rules, insul
Among the U.S. Food and Drug Administration s responsibilities are approval and regulation of pharmaceutical drugs. In short, its responsibility is to ensure the safety and effectiveness of drugs. In the performance of this task, FDA officials can make two types of errors statistically known as the type I error and type II error.
The "Transplant Complications Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com' s offering. This report Transplant Complications Drug Development Pipeline Review, 2018, provides an overview of the pipeline landscape for transplant complications. It provides comprehensive information on the therapeutics under..
Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises. Novartis International AG/ Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises. Processed and transmitted by West Corporation.
Valley Cottage, NY 12/18/2018 Global hypercalcemia treatment market revenues are anticipated to reach US$ 9.64 Bn in 2017, up from US$ 7.86 Bn in 2015. U.S. FDA approval of denosumab for treating hypercalcemia of malignancy refractory in 2014 has boosted the use of biophosphonates. North America and Western Europe are among the leading market
Indivior, a pharmaceutical company, issued the following news release:. Indivior PLC with today's announcement and accompanying supplement published on its website is:. *Providing an update on legal matters relating to the Court of Appeals for the Federal Circuit vacating the preliminary injunction against Dr. Reddy's Laboratories, including next s
Forty-seven states and the Justice Department are investigating a price-fixing conspiracy that's driving up the cost of generic drugs in the United States. One investigator called it "most likely the largest cartel in the history of the United States." This crisis calls for action.
People for the Ethical Treatment of Animals issued the following news release:. After a meeting with PETA last week, AbbVie Inc. has become the first pharmaceutical company to officially end the cruel forced swim test. AbbVie's meeting with PETA followed the group's submission of shareholder resolutions calling on four pharmaceutical companiesAbb
Dec. 18 CONCORD A federal jury on Tuesday found a former physician's assistant "guilty of participating in a scheme in which he received kickbacks in exchange for prescribing a powerful fentanyl spray to patients in violation of federal law," announced U.S. Attorney Scott W. Murray. Christopher Clough, 44, of Dover, was charged with eight crime
Mike Kelly, R- Pa., has introduced legislation to "clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers." Mike Kelly, 1707 Longworth House Office Building, Washington, DC 20515; 202/ 225-5406; or in the district offices at 208 E. Bayfront Parkway, Ste. 102, Erie, PA 16507; 814/ 454-8
Novartis International AG/ Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises. Processed and transmitted by West Corporation. Under the terms of the agreement, Sandoz will be fully responsible for commercializing these medicines in the EU, US, Switzerland, Japan, S
New York, NY 12/19/2018 Self-Administered Medication Market: Overview. Growing prevalence of chronic diseases has led to surge in the number of disabilities and cause of death. According to Fact.MR, the global self-administered drugs market is expected to represent a value of over US$ 100,000 Mn by the end of 2026..
New York, NY 12/19/2018 Increasing level of awareness about consuming healthy food, especially among aging population is driving the demand for food products with vitamins and derivatives. Consumption of such products has also increased in emerging economies such as China, India and Brazil. Regular intake of vitamins and derivatives is extrem
Albany, NY 12/18/2018 2- Octyl cyanoacrylate adhesives are super strong adhesives which are categorized as wound glue or tissue glue. Cyanoacrylate is the generic name of a family of super strong glues that are capable of joining any type of surfaces instantly. The compound has been approved by the Food and Drug Administration for application
AcelRx Pharmaceuticals, Inc.,, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has been selected for addition to the NASDAQ Biotechnology Index . About AcelRx Pharmaceuticals, Inc. AcelRx Pharmaceuticals, Inc. is a specialty.
SEATTLE and VANCOUVER, British Columbia, Dec. 18, 2018/ PRNewswire/ Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided a clinical development update. The U.S. Food and Drug Administration has confirmed that they are i
-Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology, today provided updated data from three clinical trials for ATI-502, an investigational topical Janus.
Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the enrollment of the first patients in its 1801 Phase 1/ 2 study of 9- ING -41, a proprietary glycogen synthase kinase-3 beta inhibitor, in patients with refractory hematologic malignancies or solid tumors. "Opening enrollment on our first multicenter internat
Adamas Pharmaceuticals, Inc., a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that a new patent has been issued that covers GOCOVRI? extended release capsules by the United States Patent and Trademark Office. The 971 patent will be listed in the U.S. Food and
AGC Biologics plans to install an additional twelve 2,000 L single-use* 2 animal cell bioreactors at their Seattle site, as well as establish a brand new contract development and manufacturing facility for microbial manufacturing, a function that was previously only operated in Europe and Japan. This expansion will triple AGC's biopharmaceutical...
SAN DIEGO and FREISING, Germany, Dec. 18, 2018/ PRNewswire/ Ajinomoto Bio-Pharma Services, a fully owned subsidiary of Ajinomoto Co. Inc., and XL-protein GmbH, a privately owned German biopharmaceutical company, are pleased to announce a Strategic Alliance. Ajinomoto will apply its proprietary Corynex expression system together with XL-protein
Akaal Pharma Pty Limited today announced that it has entered into a licensing agreement for Akaal Pharma s First-in-Class, topical Spingosine-1-Phosphate-1 modulator, AKP-11, with Boston Pharmaceuticals, Inc.. Akaal Pharma has demonstrated the clinical activity of AKP-11 in multiple Phase-1 clinical studies. Under the terms of the license, Bosto